5L7E
MCR IN COMPLEX WITH ligand
5L7E の概要
エントリーDOI | 10.2210/pdb5l7e/pdb |
分子名称 | Mineralocorticoid receptor, NCOA1 peptide, 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID, ... (8 entities in total) |
機能のキーワード | mineralocorticoid receptor 2, signaling protein |
由来する生物種 | Homo sapiens (Human) 詳細 |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 36894.21 |
構造登録者 | |
主引用文献 | Nordqvist, A.,O'Mahony, G.,Friden-Saxin, M.,Fredenwall, M.,Hogner, A.,Granberg, K.L.,Aagaard, A.,Backstrom, S.,Gunnarsson, A.,Kaminski, T.,Xue, Y.,Dellsen, A.,Hansson, E.,Hansson, P.,Ivarsson, I.,Karlsson, U.,Bamberg, K.,Hermansson, M.,Georgsson, J.,Lindmark, B.,Edman, K. Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity. ChemMedChem, 12:50-65, 2017 Cited by PubMed Abstract: The mineralocorticoid receptor (MR) is a nuclear hormone receptor involved in the regulation of body fluid and electrolyte homeostasis. In this study we explore selectivity triggers for a series of nonsteroidal MR antagonists to improve selectivity over other members of the oxosteroid receptor family. A biaryl sulfonamide compound was identified in a high-throughput screening (HTS) campaign. The compound bound to MR with pK =6.6, but displayed poor selectivity over the glucocorticoid receptor (GR) and the progesterone receptor (PR). Following X-ray crystallography of MR in complex with the HTS hit, a compound library was designed that explored an induced-fit hypothesis that required movement of the Met852 side chain. An improvement in MR selectivity of 11- to 79-fold over PR and 23- to 234-fold over GR was obtained. Given the U-shaped binding conformation, macrocyclizations were explored, yielding a macrocycle that bound to MR with pK =7.3. Two protein-ligand X-ray structures were determined, confirming the hypothesized binding mode for the designed compounds. PubMed: 27897427DOI: 10.1002/cmdc.201600529 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.86 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード